Sheba Medical Center
Ramat Gan, Israel
NCT Number: NCT06350669
A randomized controlled trial to assess the efficacy of an app-assisted vestibular rehabilitation in increasing adherence to VR and treatment outcomes
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Ramat Gan, Israel
Vestibular Rehabilitation (VR) home exercises, prescribed by physiotherapists, are the main treatment for vestibular dysfunction. However, reports by clinicians indicate that patients do not fully comply with the treatment. Advances in technology and tele-rehabilitation have the potential to facilitate adherence to home exercise, if they are designed to overcome the barriers for practice. We plan to continue and expand our previous feasibility study with the vestibular phone app, in order to examine the effects of an app-assisted VR program on adherence and treatment outcomes. The patients in this study will be randomly assigned to the intervention (app-assisted vestibular rehabilitation) or the control group (standard vestibular rehabilitation, no app).
Tests and measurements for both groups will be done at three time points:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The standard vestibular rehabilitation process, with the support of a phone app throughout the process
Time frame: At the end of Cycle 1 (each cycle is 4-6 weeks)
Quantitative data on adherence to home exercise will be extracted from users' phone application database (intervention group) or from records in a diary / logs (control group)
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
Assesses balance, walking ability and also used as a screening test for the risk of falls by assessing the function of the lower limbs. The individual is required to get up from sitting on a chair, walk 3 meter forward at a normal pace, turn around and return to a sitting position. The examiner times this sequence
Time frame: At the beginning of Cycle 1 (each cycle is 4-6 weeks)
Characteristics of patients
Time frame: At the the beginning of Cycle 1 (each cycle is 4-6 weeks)
The routine assessment of vestibular functions, with fixation and without fixation. These functions include observation of gait, posture, gaze / detection of spontaneous nystagmus and it's characteristics, Vestibulo-Ocular reflex (VOR), head impulse test, head shaking nystagmus, dix-hallpike test, supine roll test and dynamic visual acuity (DVA)
Time frame: At the the beginning of Cycle 1 (each cycle is 4-6 weeks)
The routine assessment of oculomotor functions: Saccades, Smooth-Pursuit, Vestibulo-Ocular Reflex cancellation (VORc) test, Convergence, single cover and cover-uncover test
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
Subjective ranking of the severity of symptoms of dizziness and nausea in sitting position, standing and walking
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
The Hebrew version of the Dizziness Handicap Inventory (DHI) questionnaire
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
A questionnaire that measures the patient's level of balance confidence in performing daily activities
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
Assesses patient's ability to maintain balance while walking in the presence of external demands
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
Estimates walking speed in meters per second of a short distance (10-meter walking distance)
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
Measures the distance the subject can walk in two minutes, aiming to assess endurance, functional mobility and gait
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
Tests visual acuity during head movement, which rely on the behavior of the Vestibulo-ocular reflex (VOR)
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
A test to evaluate the angular VOR and the function of the superior and inferior vestibular nerves
Time frame: At the beginning of Cycle 1, the end of Cycle 1 and the end of Cycle 2 (each cycle is 4-6 weeks)
To provide the examiner with complementary information about peripheral vestibular function. This is a sensitive indicator of residual vestibular function as well as the usual VOR (Vestibulo-ocular reflex) gain measure
Time frame: At the end of Cycle 1 (each cycle is 4-6 weeks)
Quantitative data exercise difficulty levels and symptoms severity will be extracted from users' phone application database
Time frame: By the end of Cycle 1 (each cycle is 4-6 weeks)
A questionnaire for assessing the degree of cognitive reserve. Cognitive reserve describes the resilience of the brain to damage, and is used to interpret individual differences in susceptibility to cognitive impairment in the presence of brain changes associated with age or disease.
University of Haifa
Other
App-supported Vestibular Rehabilitation (Randomized Controlled Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05436067
Balance; Distorted, Dizziness
Kansas City, Kansas, United States
View Trial DetailsNCT06563076
Ear Diseases, Labyrinth Diseases
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsNCT05846711
BPPV, Benign Paroxysmal Positional Vertigo
Aalborg, North Denmark, Denmark
View Trial DetailsNCT03799991
Alzheimer Disease, Brain Diseases
Baltimore, Maryland, United States
View Trial Details